Sepsis: Immunopathology, Immunotherapies, and Future Perspectives

TAVACI T., Akgun N.

Eurasian Journal of Medicine, cilt.54, 2022 (ESCI) identifier identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 54
  • Basım Tarihi: 2022
  • Doi Numarası: 10.5152/eurasianjmed.2022.22314
  • Dergi Adı: Eurasian Journal of Medicine
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, CINAHL, Directory of Open Access Journals, TR DİZİN (ULAKBİM)
  • Anahtar Kelimeler: Sepsis, immunotherapy, immunopathology, TUMOR-NECROSIS-FACTOR, SEPTIC SHOCK, DOUBLE-BLIND, INDUCED IMMUNOSUPPRESSION, MONOCLONAL-ANTIBODY, ANTIOXIDANT ENZYMES, IMMUNE DYSFUNCTION, IMPROVES SURVIVAL, CECAL LIGATION, RAT MODEL
  • Atatürk Üniversitesi Adresli: Evet

Özet

© 2022, AVES. All rights reserved.Sepsis is a syndrome that includes physiological, pathological, and biochemical abnormalities resulting from the host immune response to infection. Despite the improved treatment modalities in recent years, the incidence and mortality of sepsis are still increasing. Sepsis immunopathology is increasingly attracting the attention of researchers. The successes experienced with immunotherapeutics in the treatment of cancer and coronavirus disease 2019, which are diseases with similar pathophysiological features and common immune defects with sepsis, have given rise to the hope that similar successes can be achieved in the treatment of sepsis. In this review, future perspectives on the immunopathology of sepsis and immunotherapeutics are presented to improve the current understanding of the disease.